The ASX-listed investment manager smashed analysts’ expectations thanks to the stellar performance of its growth house.

Alongside the study, Arris developed a new carbon fibre plate for Brooks’ Hyperion Elite 4 running shoe in early 2024. The ...

Merck Announces Decision to Stop Phase 3 HYPERION Trial Evaluating WINREVAIR™ (sotatercept-csrk) Early and Move to Final ...

Enter NYXI with its updated Hyperion 2 Joy-Con pads, pitched as "the ultimate replacement" for the real Mc-Con. They don't ...

Federal prosecutors and New York officials sparred after an illegal immigrant was released from custody despite an outstanding federal arrest warrant.

All patients in the trial will have the opportunity to resume or begin treatment with Winrevair, the company said.

In close partnership with ALLIED Feather + Down (AF+D) and premium performance wear manufacturer Active Apparel Group, Templa ...

The Phase III HYPERION trial was stopped early after strong positive interim results from the ZENITH trial demonstrated the ...

Q4 2024 Earnings Call Transcript February 4, 2025 Merck & Co., Inc. misses on earnings expectations. Reported EPS is $1.72 ...

The phase 3 HYPERION trial of Winrevair in adults with newly diagnosed pulmonary arterial hypertension functional class two ...

The HYPERION study will be stopped early due to positive efficacy data from across the sotatercept clinical program.

Merck (MRK) announced the Phase 3 HYPERION study evaluating WINREVAIR versus placebo in recently diagnosed adults with pulmonary arterial ...